Oncolytic virotherapy

Clinical landscape of oncolytic virus research in 2020
Nicholas Macedo, David M Miller, Rizwan Haq, Howard L Kaufman

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e001486; DOI: 10.1136/jitc-2020-001486
Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
Bo-Kyeong Jung, Hae Young Ko, Hyunji Kang, JinWoo Hong, Hyo Min Ahn, Youjin Na, Hyeongi Kim, Jin Su Kim, Chae-Ok Yun

Journal for ImmunoTherapy of Cancer Aug 2020, 8 (2) e000763; DOI: 10.1136/jitc-2020-000763
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
Erica B Flores, Bulent A Aksoy, Eric Bartee

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000804; DOI: 10.1136/jitc-2020-000804
Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety
Yan Ge, Haiyan Wang, Jinghua Ren, Weilin Liu, Lingjuan Chen, Hongqi Chen, Junjie Ye, Enyong Dai, Congrong Ma, Songguang Ju, Zong Sheng Guo, Zuqiang Liu, David L Bartlett

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000710; DOI: 10.1136/jitc-2020-000710
Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8⁺ T-cell functionality
Seyedeh-Raheleh Niavarani, Christine Lawson, Marie Boudaud, Camille Simard, Lee-Hwa Tai

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000465; DOI: 10.1136/jitc-2019-000465
Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy
Mee Y. Bartee, Parker C. Dryja, Eric Bartee

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 11; DOI: 10.1186/s40425-018-0496-6

Main menu

Oncolytic virotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic virotherapy

Pages